|
Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study. |
|
|
Employment - Agios; SERVIER |
Stock and Other Ownership Interests - Agios |
|
|
Employment - Alnylam; SERVIER |
Stock and Other Ownership Interests - 10x Genomics; Alnylam; Altimmune; VBI Vaccines |
Travel, Accommodations, Expenses - Alnylam |
|
|
No Relationships to Disclose |
|
|
Employment - Agios; SERVIER |
Stock and Other Ownership Interests - Agios |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Legend Biotech; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); Sillajen; SOBI (I); Surface Oncology; TheraBionic; twoXAR; Vector Health; Yiviva; Yiviva |
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst) |
Travel, Accommodations, Expenses - Polaris |